Lack of consistent biomarker assays may lead to ‘imprecision’ oncology

Biomarker assays might be letting down the precision oncology team due to a lack of standardisation between tests, platforms and positivity thresholds, pathologists say. According to a Comment article in the Lancet Oncology, the current FDA process of approving drugs with the companion diagnostics used in clinical trials isn’t always helping with consistency of biomarker ...

Already a member?

Login to keep reading.

© 2022 the limbic